CERVICAL SQUAMOUS CELL CARCINOMA
Clinical trials for CERVICAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tame tough cancers
Disease control Recruiting nowThis study tests a new drug (HMBD-001) combined with standard treatments (cetuximab, with or without docetaxel) in people with advanced squamous cell cancers that have spread. The goal is to see if the combination is safe and can help control the cancer or slow its growth. About …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug ALE.P02 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to target a protein called Claudin-1 found on these cancer cells. The main goals are to check the drug's safety, find th…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for tough cancers: EVOLVE104 trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell cancers (lung, esophagus, skin, and others) that have not responded to standard treatments. About 160 participants will receive the drug to see if it …
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New Antibody-Drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ALE.P03 in adults with advanced cancers (cervical, lung, colorectal, bile duct, or bladder) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called Claudin-1 found on these tumor…
Matched conditions: CERVICAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Alentis Therapeutics AG • Aim: Disease control
Last updated May 04, 2026 16:22 UTC